Inspire Pharmaceuticals Inc.

PositionWill go ahead without Genentech - Brief Article

Inspire Pharmaceuticals Inc. has had its share of downers in the first half of 2001. First, the six-year-old Durham company, which raised $69 million in an August stack offering, stopped enrolling new patients in a test for a chronic-bronchitis drug. Then its partner in developing the drug and one aimed at treating cystic fibrosis and sinusitis, San Fransisco-based Genentech Inc., backed...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT